Asthma and lower airway disease
Developmental patterns in the nasopharyngeal microbiome during infancy are associated with asthma risk

https://doi.org/10.1016/j.jaci.2020.10.009Get rights and content

Background

Studies indicate that the nasal microbiome may correlate strongly with the presence or future risk of childhood asthma.

Objectives

In this study, we tested whether developmental trajectories of the nasopharyngeal microbiome in early life and the composition of the microbiome during illnesses were related to risk of childhood asthma.

Methods

Children participating in the Childhood Origins of Asthma study (N = 285) provided nasopharyngeal mucus samples in the first 2 years of life, during routine healthy study visits (at 2, 4, 6, 9, 12, 18, and 24 months of age), and during episodes of respiratory illnesses, all of which were analyzed for respiratory viruses and bacteria. We identified developmental trajectories of early-life microbiome composition, as well as predominant bacteria during respiratory illnesses, and we correlated these with presence of asthma at 6, 8, 11, 13, and 18 years of age.

Results

Of the 4 microbiome trajectories identified, a Staphylococcus-dominant microbiome in the first 6 months of life was associated with increased risk of recurrent wheezing by age 3 years and asthma that persisted throughout childhood. In addition, this trajectory was associated with the early onset of allergic sensitization. During wheezing illnesses, detection of rhinoviruses and predominance of Moraxella were associated with asthma that persisted throughout later childhood.

Conclusion

In infancy, the developmental composition of the microbiome during healthy periods and the predominant microbes during acute wheezing illnesses are both associated with the subsequent risk of developing persistent childhood asthma.

Key words

Microbiome
children
asthma
development
birth cohort

Abbreviations used

ASV
Amplicon sequence variant
COAST
Childhood Origins of Asthma birth cohort study
GEE
Generalized estimating equation
MPG
Microbiome predominance group
RSV
Respiratory syncytial virus
RV
Rhinovirus

Cited by (0)

Supported by National Institutes of Health, National Heart, Lung, and Blood Institute (grant PO1 HL70381), the National Center for Advancing Translational Sciences (grant UL1TR000427), and the Office of the National Institutes of Health Director (grant no. UG3/UH3 OD023282). M.I. was supported by the Australian National Health and Medical Research Council (grant 1049539). H.H.F.T. was supported by an Australian National Health and Medical Research Council PhD scholarship. K.E.H. was supported by a Senior Medical Research Fellowship from the Viertel Foundation of Victoria.

Disclosure of potential conflict of interest: J. E. Gern is a paid consultant to Ena Therapeutics, Meissa Vaccines, MedImmune, and Regeneron; he has stock options in Meissa Vaccines, as well as a US patent titled “Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines” and a US patent titled “Adapted Rhinovirus C.” The rest of the authors declare that they have no relevant conflicts of interest.

Anna Lang, MD, is currently at the Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Wash, and Michael D. Evans, MD, is currently at Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minn.

These authors contributed equally to this study.

View Abstract